Bachrodt Amy 4

What Happened

• Amy Bachrodt, SVP Finance at Maze Therapeutics, exercised 5,000 stock options on Jan 22, 2026 (2,497 and 2,503 shares) at an exercise price of $10.42/share, costing $52,100 in total. On the same day she sold 5,000 common shares in the open market at a weighted average price of $45.52/share, generating proceeds of $227,612. The filing also shows two derivative "Disposed" entries at $0.00 related to the exercised options (reported as derivative dispositions).

Key Details

• Transaction date: January 22, 2026.
• Exercise: 5,000 options exercised at $10.42 each (total cost $52,100).
• Sale: 5,000 shares sold, weighted avg price $45.52; total proceeds $227,612. Reported sale price range $45.00–$45.93 (multiple transactions).
• Footnotes: Sale effected under a Rule 10b5-1 trading plan adopted Sept 29, 2025 (F1). Vesting schedules for the options are monthly (first tranches Apr 1, 2021 and Mar 1, 2022 per F3/F4). Weighted-average sale price detailed in F2.
• Shares owned after transaction: not specified in this filing.
• Filing timeliness: filed Jan 26, 2026 for a Jan 22, 2026 transaction (filed within required reporting window).

Context

• This sequence—exercising options and selling the resulting shares the same day—is commonly a way for insiders to monetize vested options. The $0.00 derivative dispositions reported alongside the exercise are typical reporting entries when shares are netted or withheld in connection with option exercises; here the open‑market sale of 5,000 shares produced the cash proceeds shown. The 10b5-1 plan note indicates the sales were prearranged and scheduled.